Celgene

GPTKB entity

Statements (71)
Predicate Object
gptkbp:instance_of gptkb:pharmaceuticals
gptkbp:acquired_by gptkb:Bristol-Myers_Squibb
gptkbp:acquisition gptkb:Juno_Therapeutics
gptkb:Celgene_Cellular_Therapeutics
$74 billion
Acquired by Bristol-Myers Squibb
gptkbp:acquisition_year 2019-01-03
gptkbp:ceo gptkb:Mark_J._Alles
gptkbp:clinical_trial gptkb:Oncology
gptkb:CAR_T-cell_therapy
oncology
hematology
immunology
solid tumors
gptkbp:community_engagement gptkb:healthcare_professionals
patient advocacy
research institutions
gptkbp:employees 7,000 (2019)
gptkbp:focus gptkb:cancer_treatment
oncology
hematology
immunology
Inflammatory Diseases
gptkbp:founded gptkb:1986
gptkbp:founder gptkb:Sol_J._Barer
gptkbp:global_presence over 70 countries
gptkbp:headcount 7,000 (2019)
gptkbp:headquarters gptkb:Summit,_New_Jersey
gptkb:United_States
gptkbp:healthcare biologics
small molecules
gene therapies
https://www.w3.org/2000/01/rdf-schema#label Celgene
gptkbp:industry gptkb:pharmaceuticals
gptkbp:market_cap $74 billion (2019)
gptkbp:partnership Partnership with Juno Therapeutics
Partnership with Amgen
Abb Vie for Imbruvica
Amgen for Blincyto
Bristol-Myers Squibb for Opdivo
gptkbp:partnerships gptkb:Bristol-Myers_Squibb
gptkb:Amgen
gptkb:Abb_Vie
gptkbp:products gptkb:Revlimid
gptkb:Pomalyst
gptkb:Thalomid
gptkbp:related_products gptkb:Lenalidomide
gptkb:Pomalidomide
gptkb:Thalidomide
gptkb:Revlimid
gptkb:Pomalyst
gptkb:Thalomid
Idhifa
gptkbp:research_focus gptkb:Gene_Therapy
genetic disorders
autoimmune diseases
Biologics
cancer therapies
Cellular Immunotherapy
gptkbp:revenue $15.2 billion (2019)
gptkbp:stock_symbol gptkb:CELG
gptkbp:subsidiaries gptkb:Juno_Therapeutics
gptkb:Celgene_Cellular_Therapeutics
gptkbp:sustainability_initiatives community support
ethical practices
environmental responsibility
gptkbp:traded_on gptkb:NASDAQ
gptkbp:type gptkb:public_company
gptkbp:website www.celgene.com
gptkbp:bfsParent gptkb:biotechnology
gptkbp:bfsLayer 3